Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study

The European FK 506 Multicentre Psoriasis Study Group: Clinical Centers and Principal Investigators, A. Y. Rubins (Member of the Working Group), I. Hartmane (Member of the Working Group)

Research output: Contribution to journalArticlepeer-review

154 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study'. Together they form a unique fingerprint.

Medicine & Life Sciences